World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
78
Citations
36335
World Ranking
17809
National Ranking
8882

Donna Przepiorka publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Donna Przepiorka sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 347 publications — 27th percentile

27% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Donna Przepiorka D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Donna Przepiorka sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 78 D-Index — 12th percentile

12% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Donna Przepiorka is affiliated with the US Food and Drug Administration in the United States and has contributed extensively to the field of medicine, with a focus on hematology and oncology.

Their research spans several key subfields including hematology, oncology, public health, environmental and occupational health, pediatrics, perinatology and child health, and genetics. The main topics of their work cover:

  • Acute Myeloid Leukemia Research
  • CAR-T cell therapy research
  • Acute Lymphoblastic Leukemia research
  • Hematopoietic Stem Cell Transplantation
  • Chronic Myeloid Leukemia Treatments
  • Renal Transplantation Outcomes and Treatments
  • Childhood Cancer Survivors' Quality of Life

Donna Przepiorka has published regularly in several scientific venues, with the highest number of publications appearing in:

  • Clinical Cancer Research (6 publications)
  • The Oncologist (2 publications)
  • Blood (2 publications)
  • JAMA (2 publications)
  • Blood Advances (1 publication)

Frequently collaborating with other researchers, their most commonly listed co-authors include:

  • R. Angelo de Claro (8 papers)
  • Marc R. Theoret (7 papers)
  • Richard Pazdur (6 papers)
  • Jonathon Vallejo (5 papers)
  • Robert Q. Le (4 papers)

Recent notable publications by Donna Przepiorka include:

  • FDA Approval Summary: Belumosudil for Adult and Pediatric Patients 12 Years and Older with Chronic GvHD after Two or More Prior Lines of Systemic Therapy, 2022, Clinical Cancer Research
  • FDA Approval Summary: Gilteritinib for Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation, 2021, Clinical Cancer Research
  • Differentiation Syndrome with Ivosidenib and Enasidenib Treatment in Patients with Relapsed or Refractory IDH-Mutated AML: A U.S. Food and Drug Administration Systematic Analysis, 2020, Clinical Cancer Research
  • FDA Approval Summary: Brexucabtagene Autoleucel for Treatment of Adults With Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia, 2022, The Oncologist
  • FDA Approval Summary: Ruxolitinib for Treatment of Chronic Graft-Versus-Host Disease after Failure of One or Two Lines of Systemic Therapy, 2022, The Oncologist

Donna Przepiorka's research is primarily centered on treatments and approvals related to various forms of leukemia and graft-versus-host disease, reflecting a strong focus on clinical advancements within oncology and hematology.

Best Publications

  • 1994 Consensus Conference on Acute GVHD Grading.

    Przepiorka D;Weisdorf D;Martin P;Klingemann Hg

  • National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease

    Madan H. Jagasia;Hildegard T. Greinix;Mukta Arora;Kirsten M. Williams

  • Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

    Sergio Giralt;Elihu Estey;Maher Albitar;Koen Van Besien

  • Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies.

    I F Khouri;M Keating;M Körbling;D Przepiorka

  • Melphalan and purine analog–containing preparative regimens: reduced-intensity conditioning for patients with hematologic malignancies undergoing allogeneic progenitor cell transplantation

    Sergio Giralt;Peter F. Thall;Issa Khouri;Xuemei Wang

  • IBMTR Severity INDEX FOR GRADING ACUTE GRAFT‐VERSUS‐HOST DISEASE: RETROSPECTIVE COMPARISON WITH GLUCKSBERG GRADE

    Rowlings Pa;Przepiorka D;Klein Jp;Gale Rp

  • Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors.

    Richard A. Nash;Joseph H. Antin;Chatchada Karanes;Joseph W. Fay

  • FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell‐Induced Severe or Life‐Threatening Cytokine Release Syndrome

    Robert Q. Le;Liang Li;Weishi Yuan;Stacy S. Shord

  • Phase III Study Comparing Methotrexate and Tacrolimus (Prograf, FK506) With Methotrexate and Cyclosporine for Graft-Versus-Host Disease Prophylaxis After HLA-Identical Sibling Bone Marrow Transplantation

    Voravit Ratanatharathorn;Richard A. Nash;Donna Przepiorka;Steven M. Devine

  • Measuring Therapeutic Response in Chronic Graft-versus-Host Disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group Report

    Stephanie J. Lee;Daniel Wolff;Carrie Kitko;John Koreth

  • Allogeneic Blood Stem Cell Transplantation for Refractory Leukemia and Lymphoma: Potential Advantage of Blood Over Marrow Allografts

    M Korbling;D Przepiorka;YO Huh;H Engel

  • CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation

    S. Giralt;J. Hester;Yang O Huh;Cheryl F Hirsch-Ginsberg

  • Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma.

    I F Khouri;J Romaguera;H Kantarjian;J L Palmer

  • Community Respiratory Virus Infections Among Hospitalized Adult Bone Marrow Transplant Recipients

    Estella Whimbey;Richard E. Champlin;Robert B. Couch;Janet A. Englund

  • Measuring Therapeutic Response in Chronic Graft-versus-Host Disease. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease

    Stephanie J. Lee;Daniel Wolff;Carrie Kitko;John Koreth

  • Allogeneic Stem Cell Transplantation for Agnogenic Myeloid Metaplasia: A European Group for Blood and Marrow Transplantation, Société Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study

    P. Guardiola;J. Anderson;G. Bandini;F. Cervantes

  • Allogeneic blood stem cell transplantation: peripheralization and yield of donor-derived primitive hematopoietic progenitor cells (CD34+ Thy-1dim) and lymphoid subsets, and possible predictors of engraftment and graft-versus-host disease.

    Martin Korbling;Yang O Huh;A. Durett;N. Mirza

  • Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease

    D. Przepiorka;N. A. Kernan;C. Ippoliti;E. B. Papadopoulos

  • FDA Approval: Blinatumomab.

    Donna Przepiorka;Chia-Wen Ko;Albert Deisseroth;Carolyn L. Yancey

  • Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals

    Paolo Anderlini;Donna Przepiorka;Richard Champlin;Martin Körbling

Frequent Co-Authors

Richard E. Champlin
Richard E. Champlin The University of Texas MD Anderson Cancer Center
Sergio Giralt
Sergio Giralt Memorial Sloan Kettering Cancer Center
Issa F. Khouri
Issa F. Khouri The University of Texas MD Anderson Cancer Center
Borje S. Andersson
Borje S. Andersson The University of Texas MD Anderson Cancer Center
Albert B. Deisseroth
Albert B. Deisseroth US Food and Drug Administration
Karen R. Cleary
Karen R. Cleary The University of Texas MD Anderson Cancer Center
John R. Wingard
John R. Wingard University of Florida
Meletios A. Dimopoulos
Meletios A. Dimopoulos National and Kapodistrian University of Athens
Paul J. Martin
Paul J. Martin Fred Hutchinson Cancer Research Center
Mary M. Horowitz
Mary M. Horowitz Medical College of Wisconsin

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in the healthcare field, but looking for flexible options or alternative career paths beyond traditional medical school? The rise of accredited online programs has opened new doors for those hoping to enter or advance within the industry without relocating or taking on significant debt.

For individuals seeking administrative roles, cheapest medical billing and coding online courses offer an affordable entry point into healthcare by teaching essential skills in medical record management and insurance processing.

For aspiring nurses, there are many cheapest online nursing programs that provide foundational training, often paving the way to licensure and clinical practice. Those who want a more advanced role can explore the most affordable online nurse practitioner programs, which prepare graduates for greater responsibility and independence in patient care.

If you’re already a nursing professional aiming to pursue research or leadership positions, accredited phd nursing programs are available fully online, often with flexible schedules. These programs enable you to contribute to medical science and higher education at the doctoral level.

Best Scientists Citing Donna Przepiorka

Trending Scientists

Recently Published Articles